Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 01 tags : Fda save search
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and CataplexyFT218 assigned PDUFA target action date of October 15, 2021
Published: 2021-03-01 (Crawled : 21:00) - biospace.com/
AVDL | $17.655 -2.41% -2.46% 440K
|
Health Technology
|
| O: 0.75%
H: 4.57%
C: 2.22%
new drug treatment fda fda acceptance drug ft218 pdufa narcolepsy
GRAM Applauds FDA Emergency Use Authorization for Johnson & Johnson COVID-19 Vaccine
Published: 2021-03-01 (Crawled : 19:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.89%
H: 0.05%
C: -1.32%
covid fda vaccine merge authorized covid-19 emergency use authorization
Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Published: 2021-03-01 (Crawled : 14:01) - globenewswire.com
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 12.3%
H: 0.84%
C: -7.15%
covid fda risk respiratory phase 3 syndros
CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution
Published: 2021-03-01 (Crawled : 14:01) - globenewswire.com
CRMD | $5.34 -2.02% -2.06% 420K
|
Health Technology
|
| O: -45.0%
H: 27.15%
C: 9.33%
fda response
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
Published: 2021-03-01 (Crawled : 13:03) - globenewswire.com
AVDL | $17.655 -2.41% -2.46% 440K
|
Health Technology
|
| O: 0.75%
H: 4.57%
C: 2.22%
new drug treatment fda drug ft218 fda acceptance narcolepsy
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Published: 2021-03-01 (Crawled : 12:05) - globenewswire.com
AGIO | $31.67 -0.44% -0.44% 540K
|
Health Technology
|
| O: -2.55%
H: 6.34%
C: 2.77%
fda drug new drug application
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -54.96%
H: 12.84%
C: 0.18%
treatment fda cancer breast cancer response metastatic breast cancer
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
Published: 2021-03-01 (Crawled : 12:00) - globenewswire.com
PLXP | $0.087 -4.6% 50M
|
Health Technology
|
| O: 18.44%
H: 15.91%
C: -0.57%
fda fda approval approval pharma
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.